PRODIGY Registry in NYHA Class III Heart Failure Patients

Endotronix, Inc.7 enrolled

Overview

This is an observational, prospective, single arm, multi-center registry to evaluate the Cordella™ Heart Failure System (CHFS) in up to 250 NYHA Class III HF patients .

The subjects in this registry will participate in the Screening Visit, and Follow-Up Visits. After the Screening Visit, eligible subjects will be trained on at-home use of the CHFS to measure BP, HR, SpO2, weight and optional ECG. They will be instructed to perform daily measurements of the parameters which will all be wirelessly transmitted to a secure website for review using the myCordella™ Patient Management Portal (PMP). Clinicians will be able to view Blood Pressure (BP), Heart Rate (HR), peripheral capillary oxygen saturation (SpO2), weight and Electrocardiogram (ECG) (optional) data through the myCordella™ PMP. Subjects will return for follow up visits at 3, 6, and 12 months after enrollment or until study termination. At Month 6, the primary endpoint will be assessed through evaluation of the subjects Quality of Life using the completed KCCQ Questions. Assessment of secondary endpoints will be performed throughout the study duration, including evaluation of adverse events, and heart failure-related hospitalizations and medication changes. Additionally, Health Economics will be assessed per subject and per site via a detailed site questionnaire.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Heart Failure NYHA Class III

Interventions

Cordella™ Heart Failure SystemDEVICE

The Cordella™ Heart Failure System electronically transfers communications and data from a set of medical devices in a heart failure patient's home to a database for storage, retrieval, and display to healthcare providers.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subject has given written informed consent 2. Male or female complex CCM eligible patients or equivalent and at least 18 years of age 3. Diagnosis of HF ≥ 3 months and NYHA Class III HF at the time of Screening 4. Subject fluent in English (written and oral) and with sufficient eyesight, hearing, and mental capacity to respond to the Cordella™ Heart Failure System audio/visual cues and operate the Cordella™ Heart Failure System 5. Subject has sufficient Cellular and/ or Wi- Fi Internet coverage at home 6. Subject agrees: 1. that the treating Investigator is their solely complex CCM physician 2. to return to the treating Investigator for all scheduled follow up visits and can return to the hospital for follow up Exclusion Criteria: 1. Subjects enrolled in another investigational trial. 2. Subjects who are unwilling or deemed by the Investigator to be unwilling to comply with the study protocol, or subjects with a history of non-compliance 3. Severe illness, other than heart disease, which would limit survival to \<1 year

Locations (4)

USC Keck School of Medicine

Los Angeles, California, United States

UCSF Medical Center

San Francisco, California, United States

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States

Craig Cardiovascular Center

Gonzales, Texas, United States

Outcomes

Primary Outcomes

Kansas City Cardiomyopathy Questionnaire (KCCQ) change from baseline to 6 month

The KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. An overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. For brevity, only the performance characteristics of the overall summary score are presented in this discussion.The answers patients give to the KCCQ's questions are used to calculate scores in ten scales: Physical Limitation, Symptom Stability, Symptom Frequency, Symptom Burden, Total Symptom, Social Limitation, Self-Efficacy, Quality of Life, Clinical Summary, Overall Summary

Time frame: Baseline- 6 month

Secondary Outcomes

Percentage of device success

Percentage of device success as documented by ability of the System to successfully transmit data (BP, HR, SpO2, weight and optional ECG) to a secure database.

Time frame: 12 months post Enrollment

Frequency of Adverse Events

Frequency and rates of adverse events(AEs) throughout the study

Time frame: 12 months post Enrollment

Heart Failure Hospitalizations

Number of HF hospitalizations, HF treatments in a hospital day-care setting, or urgent outpatient clinic HF visits

Time frame: 12 months post Enrollment

Device/system-related complications

Incidence of Device/system-related complications

Time frame: 12 months post Enrollment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.